Institute of Medical Microbiology, University of Debrecen, Nagyerdei krt, 98, Debrecen, Hungary.
Virol J. 2011 Aug 15;8:403. doi: 10.1186/1743-422X-8-403.
Human herpesvirus 6 (HHV-6), mostly variant B reactivation in renal transplant patients has been published by other authors, but the pathogenetic role of HHV-6 variant A has not been clarified. Our aims were to examine the prevalence of HHV-6, to determine the variants, and to investigate the interaction between HHV-6 viraemia, human cytomegalovirus (HCMV) infection and clinical symptoms.
Variant-specific HHV-6 nested PCR and quantitative real-time PCR were used to examine blood samples from renal transplant patients and healthy blood donors for the presence and load of HHV-6 DNA and to determine the variants. Active HHV-6 infection was proved by RT-PCR, and active HCMV infection was diagnosed by pp65 antigenaemia test.
HHV-6 viraemia was significantly more frequent in renal transplant patients compared to healthy blood donors (9/200 vs. 0/200; p = 0.004), while prevalence of HHV-6 latency was not significantly different (13/200 vs. 19/200; p > 0.05). Dominance of variant A was revealed in viraemias (8/9), and the frequency of HHV-6A was significantly higher in active infections compared with latency in renal transplant patients (8/9 vs. 2/13; p = 0.0015). Latency was established predominantly by HHV-6B both in renal transplant patients and in healthy blood donors (11/13 and 18/19). There was no statistical significant difference in occurrence of HCMV and HHV-6 viraemia in renal transplant patients (7/200 vs. 9/200). Statistical analysis did not reveal interaction between HHV-6 viraemia and clinical symptoms in our study.
Contrary to previous publications HHV-6A viraemia was found to be predominant in renal transplant patients. Frequency of variant A was significantly higher in cases of active infection then in latency.
已有其他作者发表了人类疱疹病毒 6(HHV-6),主要是变体 B 在肾移植患者中的再激活,但 HHV-6 变体 A 的致病作用尚未阐明。我们的目的是检查 HHV-6 的流行率,确定变体,并研究 HHV-6 病毒血症、人类巨细胞病毒(HCMV)感染和临床症状之间的相互作用。
使用变体特异性 HHV-6 巢式 PCR 和定量实时 PCR 检测肾移植患者和健康献血者的血液样本中 HHV-6 DNA 的存在和载量,并确定变体。通过 RT-PCR 证实活动性 HHV-6 感染,通过 pp65 抗原检测诊断活动性 HCMV 感染。
与健康献血者相比,肾移植患者的 HHV-6 病毒血症明显更为频繁(9/200 比 0/200;p=0.004),而 HHV-6 潜伏期的患病率无显著差异(13/200 比 19/200;p>0.05)。在病毒血症中发现了变体 A 的优势(8/9),并且在肾移植患者中,与潜伏期相比,活动性感染中的 HHV-6A 频率明显更高(8/9 比 2/13;p=0.0015)。在肾移植患者和健康献血者中,主要通过 HHV-6B 建立潜伏期(11/13 和 18/19)。肾移植患者中 HCMV 和 HHV-6 病毒血症的发生率无统计学显著差异(7/200 比 9/200)。在我们的研究中,统计分析并未发现 HHV-6 病毒血症与临床症状之间的相互作用。
与先前的出版物相反,在肾移植患者中发现 HHV-6A 病毒血症更为常见。与潜伏期相比,变体 A 在活动性感染中的频率明显更高。